Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.5, and our video podcast, CANCER BUZZ TV.



In This Section

Home / Learn / Cancer Types / Lung Cancer / Best Practices in Early-Stage NSCLC

Best Practices in Early-Stage NSCLC

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85 percent of all cases. The current standard of care for operable patients diagnosed in the early stages of NSCLC is curative surgery followed by adjuvant chemotherapy. However, more than half of these patients experience recurrence and will develop metastatic disease. To address this, several emerging therapies are being investigated for use in patients with early-stage NSCLC for their effectiveness in delaying disease progression following surgery.

These therapies are just a few of the many new cancer treatment options flooding the market. In 2019, the FDA approved 11 new therapeutic agents or expansions in indications for existing drugs used in oncology and hematology practice. With these new approvals and updates to clinical practice guidelines, oncology clinicians are challenged to keep informed about the latest clinical advances to make the best evidence-based treatment decisions for their patients.

In the evolving treatment landscape for patients with NSCLC, it is important for clinicians to gain a full understanding of optimal treatment selection and sequencing strategies, the integration of new therapies into practice, and the consensus-aligned management of treatment-related adverse events.

This project, Best Practices in Early Stage NSCLC, will promote online collaborations among clinicians involved in the care of patients with early-stage NSCLC. The project’s digital curriculum will incorporate real-time activities; collaborative, small group discussions and tasks; self-study modules; and a social learning platform.

At the end of this educational activity, participants will be able to:
  • Discuss emerging data from ongoing studies of targeted therapies in the adjuvant setting for early-stage NSCLC.
  • Review recent clinical data from emerging studies of immunotherapy with checkpoint inhibitors in the neoadjuvant and adjuvant/consolidation setting to optimize survival for patients with early-stage NSCLC.
  • Assess the role of biomarkers in treatment selection for early-stage NSCLC.
  • Implement strategies to improve care coordination within the interprofessional cancer care team to improve patient outcomes in early-stage NSCLC.

ACCC is currently recruiting Group Leaders (3-4 hours time over 8 weeks; honorarium provided) and Group Participants (2.5 hours time over 8 weeks).
More Details

For more information about this opportunity, please contact Rukiya Wongus, Program Manager, ACCC Provider Education.